Cost Effectiveness of Lopinavir/Ritonavir Compared with Atazanavir in Antiretroviral-Naive Patients: Modelling the Combined Effects of HIV and Heart Disease

By Simpson Kit N.  

Clinical Drug Investigation, Vol. 27, Iss. 1, 2007-01 ,pp. : 67-74

Adis International

Access to resources Recommend Favorite

Cost-Efficacy Comparison among Three Antiretroviral Regimens in HIV-1 Infected, Treatment-Experienced Patients

By Ruof Jörg  

Clinical Drug Investigation, Vol. 27, Iss. 7, 2007-01 ,pp. : 469-479

Adis International

Access to resources Recommend Favorite

Randomised Trial of Two Different Daily Doses of Interferon- versus Classical Therapy in Treatment-Naïve Patients with Chronic Hepatitis C

By Montalto G.  

Clinical Drug Investigation, Vol. 22, Iss. 9, 2002-01 ,pp. : 623-631

Adis International

Access to resources Recommend Favorite

Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIV

By Ma Qing   Brazeau Daniel   Zingman Barry S   Reichman Richard C   Fischl Margaret A   Gripshover Barbara M   Venuto Charles S   Slish Judianne C   DiFrancesco Robin   Forrest Alan   Morse Gene D  

Pharmacogenomics, Vol. 8, Iss. 3, 2007-03 ,pp. : 227-235

Future Medicine

Access to resources Recommend Favorite

Meta-analysis of once-daily and twice-daily lopinavir/ritonavir combined with NRTIs in HIV-1-infected, antiretroviral-naive patients

By van Wyk Jean   Qaqish Roula   Hollar Kimberly   White Kelly   D’’Amico Ronald   Norton Michael   Chiu Yi-Lin   King Martin  

Future Virology, Vol. 7, Iss. 1, 2012-01 ,pp. : 103-113

Future Medicine

Access to resources Recommend Favorite